Caricamento...
Mortality Benefit of Alirocumab: A Bayesian Perspective
BACKGROUND: The ODYSSEY OUTCOMES (Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome) trial demonstrated that alirocumab reduced major cardiovascular events. However, because of the hierarchical testing strategy used for the multiple outcomes examined, the observed reduction in all...
Salvato in:
| Pubblicato in: | J Am Heart Assoc |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6818032/ https://ncbi.nlm.nih.gov/pubmed/31599200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.013170 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|